BI-2493
Based on 4 publication(s) in Google Scholar
BI-2493 is a structural analogue of BI-2865 and a highly selective and orally active pan-KRAS inhibitor. BI-2493 can attenuate tumor growth. BI-2493 can be used for cancer iseases research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.79%
- CAS 番号: 2937344-16-4
- 分子式: C24H27N7OS
- 分子量:461.58
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
MedChemExpress(MCE)の使用を引用している文献 BI-2493
More
生物活性
製品説明
IC50 & Target
|
K-Ras WT |
体外実験
BI-2493 (0-10 μM, 72 h) inhibits the proliferation of KRAS mutant cancer cell lines in a concentration-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ASPC1 cells (G12D), HPAC cells (G12D), H727 cells (G12V) (BaF3 cells transduced with a virus derived from plasmids expressing KRAS G12D or G12V mutants)
-
Concentration:0, 100 nM, 1000 nM, 10000 nM
-
Incubation Time:72 h
-
Result:Effectively inhibited the proliferation of cancer cells ASPC1 (G12D), HPAC (G12D), and H727 (G12V)
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LS513/GP2d/HPAC/SW620/MIAPACA2-derived xenograft NMRI mice models
-
Dosage:90 mg/kg
-
Administration:Oral gavage (p.o.), twice daily for 21 days
-
Result:Reduced tumor growth in mice carrying KRAS G12C, G12D, G12V, and A146V mutation models, without causing significant toxicity to the mice.
化学情報
-
CAS 番号 2937344-16-4
-
性状 Solid
-
分子量 461.58
-
分子式 C24H27N7OS
-
Color Off-white to yellow
-
SMILES
N#CC1=C(N)SC2=C1[C@]3(CCC2)C4=C(CCC3)C(C5=NC(N6[C@H](CNCC6)C)=NC=C5)=NO4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants. [Abstract]2026 Mar 6:OF1-OF20. PMID: 41790032 -
Nat Cancer
The MEK-RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers. [Abstract]2026 Jan;7(1):116-130. PMID: 41482524 -
Nat Commun
Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status. [Abstract]2025 Nov 11;16(1):9923. PMID: 41219185 -
bioRxiv
2025 Aug 2:2025.07.31.667978. PMID: 40766426
溶剤 & 溶解度
体外:
DMSO : 50 mg/mL (108.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.71 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.71 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1665 mL | 10.8324 mL | 21.6647 mL | 54.1618 mL |
| 5 mM | 0.4333 mL | 2.1665 mL | 4.3329 mL | 10.8324 mL | |
| 10 mM | 0.2166 mL | 1.0832 mL | 2.1665 mL | 5.4162 mL | |
| 15 mM | 0.1444 mL | 0.7222 mL | 1.4443 mL | 3.6108 mL | |
| 20 mM | 0.1083 mL | 0.5416 mL | 1.0832 mL | 2.7081 mL | |
| 25 mM | 0.0867 mL | 0.4333 mL | 0.8666 mL | 2.1665 mL | |
| 30 mM | 0.0722 mL | 0.3611 mL | 0.7222 mL | 1.8054 mL | |
| 40 mM | 0.0542 mL | 0.2708 mL | 0.5416 mL | 1.3540 mL | |
| 50 mM | 0.0433 mL | 0.2166 mL | 0.4333 mL | 1.0832 mL | |
| 60 mM | 0.0361 mL | 0.1805 mL | 0.3611 mL | 0.9027 mL | |
| 80 mM | 0.0271 mL | 0.1354 mL | 0.2708 mL | 0.6770 mL | |
| 100 mM | 0.0217 mL | 0.1083 mL | 0.2166 mL | 0.5416 mL |